Medlouxx PPR

Supported by a 1200 subject controlled clinical study, Medlouxx PPR was the first large scale clinical study to show efficacy of photodynamic viral inactivation against CoVID-19.

 

What is photodynamic Viral inactivation? 

Photodynamic inactivation uses specific wavelengths of light to activate special compounds that leads to the formation of reactive oxygen species which can literally render the CoVID-19 virus powerless. It’s not a new concept but this is the first large scale peer reviewed human study to clearly demonstrate this effect, and certainly the first published study to demonstarte that CoVID-19 can be treated effectively in human subjects using antimicrobial photodynamic inactivation.

 
 
 
 

Endorsed by the German State government

 

Benefits of Medlouxx Treatments

The Medlouxx PPR treatment significantly increases the likelihood of a mild course of illness from CoVID-19 by essentially eradicating the virus before it has had a chance to spread from the initial site of infection to the lungs and other organs. The primary benefit of the treatment is to dramatically reduce the need for hospitalization, ICU admission and death due to CoVID-19 infection. This benefit is observed even in the elderly and in individuals at greater risk due to co-morbidities. 

Perhaps of even greater importance from a public health perspective, another major benefit is that the Medlouxx PPR protocol promises to break the cycle of transmission by immediately eliminating viral load from the nose and mouth (the main source of infectious viral droplets). We are confident that this solution can reduce the heavy toll on our healthcare systems and facilitate the safe re-opening of our economies.

We believe Medlouxx PPR also has significant potential for treating other respiratory infections including influenza, so this protocol will offer benefits well into the future. 


Medlouxx PPR Overall Results

The treatment involves a medically recognized approach referred to as antimicrobial photodynamic therapy (aPDT). Blood banks have long relied on this rapidly effective technique to eradicate viruses and other dangerous pathogens from blood prior to transfusion. A similar approach was shown to be highly effective against CoVID-19 in a controlled clinical study of 1200 subjects. In view of the staggering CoVID-19 toll and the promising results obtained, we published an interim study report in the American Journal of Virology and Disease in May 2020. This interim report demonstrated statistically significant results at only half the projected sample size: 

  • an 83% reduction in hospital admissions,

  • 90% reduction in ICU admissions and

  • 80% reduction in the death rate.

Imagine what a difference this treatment can make to the healthcare system, families impacted by this horrible disease and the ability to resume normal business activity!

 
 

CoVID-19 Interim Study Highlights


American Journal of Virology and Disease

  • Our recently published study clearly shows that CoVID-19 can be effectively treated, if treatment is administered at the early stages of infection. 

  • The study, conducted by Dr. Detlef Schikora in Germany reports on 600 patients: 300 patients who received the active treatment protocols and 300 who were control subjects

  • The full study of 1200 subjects was completed in November 2020.

  • The aim of the treatment was to convert CoVID-19 from a devastating infection to a mild infection that resolves quickly without the need for hospital admission.

  • We observed that almost twice as many patients that were treated only had a mild fever lasting for a week or less, compared to those who didn’t receive treatment. It’s very important to note these mild symptoms were observed across all ages, including the elderly and those with other medical conditions.

  • The definition of mild symptoms: mild fever which lasted for a maximum of 1 week. 

  • There was an 83% reduction in hospital admissions and 91% reduction in ICU admissions


 


  • The death rate was 5 times LOWER in the active treatment subjects at the mid point of the study (10 times LOWER by the end of the study)

  • Treatment was provided to patients with confirmed PCR CoVID-19 tests, in the early stages of infection. This innovative protocol focused on reducing the viral load in both the oral cavity (mouth) and nose and throat with photodynamic viral inactivation.

  • Formation of specific CoVID-19 antibodies was confirmed in 96% of actively treated subjects.

  • There were no known treatment related adverse events.

This was an important breakthrough!! We now have a treatment available which is truly effective, but at the same time is very safe.

For more information on Medlouxx PPR or the CoVID-19 Home Care Program contact us through this website or at info@LuminnovaHealth.com